Viraday

Viraday is a combination tablet that contains Emtricitabine (200mg), Tenofovir disoproxil fumarate (300mg), and Efavirenz (600mg), antiretroviral medications used to treat human immunodeficiency virus (HIV) infection in adults.

Composition:

• Emtricitabine: 200mg
• Tenofovir disoproxil fumarate: 300mg
• Efavirenz: 600mg
• Tablet core: lactose monohydrate, magnesium stearate, silicon dioxide
• Film coating: hypromellose, polyethylene glycol, titanium dioxide

Mechanism of Action:

Viraday works by inhibiting the activity of HIV reverse transcriptase, an enzyme necessary for the virus to replicate. The combination of Emtricitabine, Tenofovir disoproxil fumarate, and Efavirenz has a synergistic effect in suppressing HIV replication.

Emtricitabine:

• Emtricitabine is a nucleoside reverse transcriptase inhibitor that inhibits the activity of HIV reverse transcriptase.
• It is converted into its active form, emtricitabine triphosphate, which is incorporated into the viral DNA, terminating the chain and preventing the virus from replicating.

Tenofovir disoproxil fumarate:

• Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor that inhibits the activity of HIV reverse transcriptase.
• It is converted into its active form, tenofovir diphosphate, which is incorporated into the viral DNA, terminating the chain and preventing the virus from replicating.

Efavirenz:

• Efavirenz is a non-nucleoside reverse transcriptase inhibitor that inhibits the activity of HIV reverse transcriptase.
• It binds to the active site of HIV reverse transcriptase, preventing it from replicating the viral genome.

Uses:

Viraday is used to treat HIV infection in adults. It is recommended for patients who have not previously received antiretroviral therapy or who have failed other antiretroviral regimens.

Dosage:

The recommended dosage of Viraday is one tablet once daily, taken with food.

Side Effects:

Common side effects of Viraday include:

• Headache
• Nausea
• Vomiting
• Fatigue
• Dizziness
• Insomnia
• Rash
• Abnormal dreams
• Increased blood lipids
• Neuropathy (nerve damage)
• Lactic acidosis (build-up of lactic acid in the blood)

Recommendation:

Viraday should be used under the guidance of a healthcare professional. Patients should be monitored regularly for liver function tests, lipid profiles, and glucose levels.

Important Note:

• Viraday is not recommended for use in patients with severe liver disease (Child-Pugh C).
• Patients with pre-existing kidney disease should be monitored closely for signs of kidney damage or toxicity.
• Patients taking other medications, including antiretroviral agents, may be at risk for interactions with Viraday.
• The safety and efficacy of Viraday in pregnant or lactating women have not been established.
• Patients should be counseled on the importance of taking concomitant therapy as prescribed by their healthcare provider.
• Patients should be monitored for neuropsychiatric symptoms, such as depression, anxiety, and sleep disorders.